Free Trial
OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

Appili Therapeutics logo
$0.03 +0.00 (+23.08%)
As of 03:54 PM Eastern

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Key Stats

Today's Range
$0.02
$0.03
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$0.05
Volume
120,918 shs
Average Volume
36,344 shs
Market Capitalization
$3.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
See More Headlines

APLIF Stock Analysis - Frequently Asked Questions

Appili Therapeutics' stock was trading at $0.0280 at the beginning of 2025. Since then, APLIF shares have decreased by 8.6% and is now trading at $0.0256.
View the best growth stocks for 2025 here
.

Appili Therapeutics Inc. (OTCMKTS:APLIF) issued its earnings results on Tuesday, August, 13th. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01).

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/13/2024
Today
1/14/2025
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-2,800,000.00
Net Margins
-450.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.52 million
Optionable
Not Optionable
Beta
-0.52
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:APLIF) was last updated on 1/14/2025 by MarketBeat.com Staff
From Our Partners